A
157.30
-4.22 (-2.61%)
Penutupan Terdahulu | 161.52 |
Buka | 161.78 |
Jumlah Dagangan | 60,065 |
Purata Dagangan (3B) | 531,843 |
Modal Pasaran | 9,496,752,128 |
Harga / Jualan (P/S) | 22.75 |
Julat 52 Minggu | |
Tarikh Pendapatan | 1 May 2025 |
Margin Keuntungan | -92.67% |
Margin Operasi (TTM) | -103.23% |
EPS Cair (TTM) | -6.58 |
Pertumbuhan Hasil Suku Tahunan (YOY) | 5.30% |
Nisbah Semasa (MRQ) | 1.04 |
Aliran Tunai Operasi (OCF TTM) | -218.93 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -133.44 M |
Pulangan Atas Aset (ROA TTM) | -22.39% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Menurun | Menurun |
Biotechnology (Global) | Menurun | Menurun | |
Stok | Ascendis Pharma A/S | Menaik | Menaik |
AISkor Stockmoo
1.4
Konsensus Penganalisis | 5.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -1.5 |
Purata Bergerak Teknikal | 0.0 |
Osilator Teknikal | 2.0 |
Purata | 1.38 |
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America. |
|
Sektor | Healthcare |
Industri | Biotechnology |
% Dimiliki oleh Orang Dalam | 0.78% |
% Dimiliki oleh Institusi | 113.42% |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 280.00 (Evercore ISI Group, 78.00%) | Beli |
Median | 228.50 (45.26%) | |
Rendah | 200.00 (Cantor Fitzgerald, 27.15%) | Beli |
Purata | 232.83 (48.02%) | |
Jumlah | 6 Beli | |
Harga Purata @ Panggilan | 168.90 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
Cantor Fitzgerald | 12 May 2025 | 200.00 (27.15%) | Beli | 154.43 |
Morgan Stanley | 05 May 2025 | 250.00 (58.93%) | Beli | 170.74 |
Evercore ISI Group | 02 May 2025 | 280.00 (78.00%) | Beli | 172.06 |
JP Morgan | 02 May 2025 | 245.00 (55.75%) | Beli | 172.06 |
18 Mar 2025 | 200.00 (27.15%) | Beli | 164.65 | |
RBC Capital | 02 May 2025 | 210.00 (33.50%) | Beli | 172.06 |
16 Apr 2025 | 205.00 (30.32%) | Beli | 158.15 | |
Wedbush | 02 May 2025 | 212.00 (34.77%) | Beli | 172.06 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
13 May 2025 | Pengumuman | New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide) |
12 May 2025 | Pengumuman | New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism |
05 May 2025 | Pengumuman | Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025 |
01 May 2025 | Pengumuman | Ascendis Pharma Reports First Quarter 2025 Financial Results |
24 Apr 2025 | Pengumuman | Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025 |
31 Mar 2025 | Pengumuman | Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |